A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis ...

In a report released today, Emily Field from Barclays maintained a Hold rating on Galapagos (0JXZ – Research Report), with a price target of ...

Last year, Incyte became the first pharma company to get approval for a drug that can re-pigment the skin in vitiligo – topical JAK1/JAK2 inhibitor Opzelura (ruxolitinib) – for patients whose ...

The FDA approval for upadacitinib was granted on the back of the SELECT phase 3 trial programme, which involved more than 4,400 patients and showed the selective JAK1 inhibitor was able to improve ...

Medscape Medical News, December 23, 2024 Novel JAK1 Inhibitor Hits the Mark in Arthritis Trial Ivarmacitinib, a novel Janus kinase 1 inhibitor, may be considered a potential treatment for patients ...

Technoderma Medicines, Inc. ('the Company'), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ...

After hours: January 10 at 7:01:28 PM EST Loading Chart for ARQT ...

002030.SZ Daan Gene Co., Ltd.